Scarica l'app Stockscreener
85.33
0.97%
0.82
Pre-mercato:
85.08
-0.25
-0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$84.51
Aprire:
$85.44
Volume 24 ore:
2.03M
Relative Volume:
0.48
Capitalizzazione di mercato:
$33.46B
Reddito:
$4.15B
Utile/perdita netta:
$535.20M
Rapporto P/E:
63.68
EPS:
1.34
Flusso di cassa netto:
$575.20M
1 W Prestazione:
-2.30%
1M Prestazione:
+19.08%
6M Prestazione:
+9.26%
1 anno Prestazione:
-33.01%
Intervallo 1D:
$84.60
$85.70
Intervallo di 1 settimana:
$83.48
$87.00
Portata 52W:
$57.52
$128.63
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Confronta DXCM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
85.33 | 34.25B | 4.15B | 535.20M | 575.20M | 1.34 |
|
ABT
Abbott Laboratories
|
132.94 | 235.23B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
106.17 | 157.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.78 | 148.87B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
81.18 | 110.72B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.22 | 45.66B | 5.54B | 4.18B | 623.10M | 7.00 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - StreetInsider
DexCom’s SWOT analysis: CGM leader faces supply challenges amid growth - Investing.com
DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move? - Smartkarma
An Intrinsic Calculation For DexCom, Inc. (NASDAQ:DXCM) Suggests It's 27% Undervalued - Yahoo Finance
Blood Glucose Monitoring (BGM) Devices Market Report 2025: Hospitals Lead in Blood Glucose Monitoring Device Usage, Home Care Grows Fastest - GlobeNewswire Inc.
DexCom (DXCM) Maintains Buy Rating as Price Target Raised to USD 102 | DXCM Stock News - GuruFocus
Citi Increases Price Target for DexCom (DXCM) to $102 | DXCM Stock News - GuruFocus
Diabetic Care Device Market Set for Significant Growth with 10.1% CAGR - GlobeNewswire Inc.
Dexcom (DXCM) Gets a Buy from Wells Fargo - The Globe and Mail
DexCom adds Renée Galá to Board of Directors By Investing.com - Investing.com Nigeria
3 Big Reasons to Love DexCom (DXCM) - Yahoo Finance
The End Of The Diabetes Industry?Eli Lilly (NYSE:LLY), DexCom (NASDAQ:DXCM) - Benzinga
FDA Approves DexCom G4 Platinum Professional Continuous Glucose Monitoring System - Medical Product Outsourcing
Can DexCom, Inc. (NASDAQ:DXCM) Maintain Its Strong Returns? - Yahoo Finance
Here's Why You Should Add DexCom Stock to Your Portfolio Now - MSN
Dexcom CEO says CGMs fit MAHA agenda ‘very nicely’; Tandem preps for new products - MedTech Dive
Is DexCom, Inc. (NASDAQ:DXCM) Trading At A 24% Discount? - simplywall.st
Do Wall Street Analysts Like DexCom Stock? - Nasdaq
DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook - Yahoo Finance
Dexcom Beats Investor Claims Over Sales Growth Potential for Now - Bloomberg Law News
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil - TradingView
Dexcom Beats Investor Claims Over Growth Potential for Now (1) - Bloomberg Law News
DexCom, Inc. (DXCM) Announces Leadership Promotion: Jacob S. Lea - GuruFocus
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO | DXCM Stock News - GuruFocus
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO - GuruFocus
DexCom (DXCM) Elevates Jake Leach to President - GuruFocus
Dexcom promotes Jake Leach to president role - MassDevice
The Zacks Analyst Blog Highlights Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx - TradingView
Dexcom Promotes Jake Leach to Expanded President, COO Role - Medical Product Outsourcing
DexCom Adds President Role to COO Jake Leach - marketscreener.com
All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy - Yahoo Finance
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns - TradingView
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case - MSN
DXCM STOCK NOTICE: Did DexCom, Inc. Commit Securities Fraud? Investors are Urged to Contact BFA Law about its Investigation if You Suffered Losses (DXCM) - ACCESS Newswire
Investor Network: DexCom, Inc. to Host Earnings Call - ACCESS Newswire
DexCom, Inc. (DXCM) Announces Key Approvals at Annual Meeting - GuruFocus
Shareholders of DexCom, Inc. Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire
Dexcom Stockholders Approve Equity Plan Amendments - TipRanks
DXCM STOCK NOTICE: DexCom, Inc. Investors that Suffered Losses are Notified a Securities Fraud Investigation has been Initiated against DXCM and are Urged to Contact BFA Law - ACCESS Newswire
DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure (NASDAQ:DXCM) - Seeking Alpha
Should You Investigate DexCom, Inc. (NASDAQ:DXCM) At US$85.34? - Yahoo Finance
Is DexCom, Inc. (DXCM) the Best Medical Device Stock to Buy Now? - Insider Monkey
Shareholders that lost money on DexCom, Inc.(DXCM) should contact Levi & Korsinsky about pending Class ActionDXCM - ACCESS Newswire
Class Action Filed Against DexCom, Inc. (DXCM) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Lost Money on DexCom, Inc. (DXCM)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Shareholders that lost money on DexCom, Inc.(DXCM) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
DexCom, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire
Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – DXCM - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of DexCom, Inc.(DXCM) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):